BLAINJECTIONSOLUTIONPriority Review
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
LYNOZYFIC (linvoseltamab-gcpt) by Rengeneron Pharmaceuticals, Inc. is linvoseltamab-gcpt is a bispecific t-cell engaging antibody that binds to the cd3 receptor expressed on the surface of t-cells and b-cell maturation antigen (bcma) expressed on the surface of multiple myeloma cells and some healthy b-lineage cells. First approved in 2025.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYNOZYFIC (linvoseltamab-gcpt) is a bispecific T-cell engaging antibody that simultaneously binds CD3 on T-cells and BCMA on multiple myeloma cells, activating immune-mediated tumor lysis. It is indicated for relapsed/refractory multiple myeloma patients. The mechanism bridges innate and adaptive immunity to overcome tumor evasion.
Growth
Early-stage launch product with moderate competitive pressure (30/100) indicates growing team buildout in commercial and medical affairs.
Mechanism of Action
Linvoseltamab-gcpt is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro, linvoseltamab-gcpt activated T-cells,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LYNOZYFIC offers exposure to a cutting-edge bispecific antibody platform in oncology during active launch phase, with opportunity to shape market positioning in a moderate-competition environment. Career growth is supported by the product's novel mechanism and the complex commercial landscape of hematologic malignancy treatment.
Brand Manager
Worked on LYNOZYFIC at Rengeneron Pharmaceuticals, Inc.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.